Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism
Open Access
- 5 January 2016
- journal article
- research article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 22 (4) , 377-380
Abstract
Rivaroxaban is a target-specific oral anticoagulant approved for the treatment of venous thromboembolism (VTE). On its major clinical trials, treatment was initiated directly with a 3-week dose of oral 15 mg twice daily followed by 20 mg every day for at least 3 months. We retrospectively evaluated an initial therapy for confirmed VTE with 1 to 18 days of enoxaparin (1 mg/kg twice daily parenteral) followed by oral rivaroxaban 20 mg every day. Of 49 patients, we found no symptomatic recurrence, no major bleeding, and only 1 clinically relevant nonmajor bleeding. We concluded in this pilot study that it is safe and effective to treat patients with enoxaparin course followed directly by a dose of 20 mg of rivaroxaban.Keywords
This publication has 12 references indexed in Scilit:
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Anticoagulant TherapyChest, 2012
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Dabigatran versus Warfarin in the Treatment of Acute Venous ThromboembolismNew England Journal of Medicine, 2009
- A Meta-analysis Comparing Low-Molecular-Weight Heparins With Unfractionated Heparin in the Treatment of Venous ThromboembolismArchives of internal medicine (1960), 2000
- Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous ThrombosisAnnals of Internal Medicine, 1999
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein ThrombosisNew England Journal of Medicine, 1996
- ANTICOAGULANT DRUGS IN THE TREATMENT OF PULMONARY EMBOLISMThe Lancet, 1960